Background Background Deaths from
Deaths from antidepressants continue to account for a antidepressants continue to account for a substantial proportion of drug-related substantial proportion of drug-related deaths. deaths.
Aims Aims To investigate the relative toxicity
To investigate the relative toxicity of the major classes of antidepressant of the major classes of antidepressant drugs, with the specific objective of drugs, with the specific objective of assessing this in relation to the cause of assessing thisin relation to the cause of death; and to analyse the deaths where death; and to analyse the deaths where there were multiple mentions of there were multiple mentions of antidepressant drugs or other antidepressant drugs or other psychoactive drugs with antidepressants. psychoactive drugs with antidepressants.
Method
Method Mortality data were collected Mortality data were collected from the National Programme of from the National Programme of Substance Abuse Deaths, and Substance Abuse Deaths, and antidepressant prescription data were antidepressant prescription data were collected. collected.
Results

Results Most deaths from
Most deaths from antidepressantdrugs were suicides (80%). antidepressantdrugs were suicides (80%). Tricyclic antidepressants (TCAs) Tricyclic antidepressants ( TCAs) accounted for more drug mentions than accounted for more drug mentions than did other antidepressant drugs (12 per did other antidepressant drugs (12 per million prescriptions). Selective serotonin million prescriptions). Selective serotonin reuptake inhibitors (SSRIs) were reuptake inhibitors (SSRIs) were associated with a significantly lower risk of associated with a significantly lower risk of toxicity, but 93% of deaths from SSRIs toxicity, but 93% of deaths from SSRIs occurred in combination with other drugs, occurred in combination with other drugs, especiallyTCAs (24.5%).In'combination' especiallyTCAs (24.5%).In'combination' deaths patients were significantly more deaths patients were significantly more likely to have had a history of drug misuse. likely to have had a history of drug misuse.
Conclusions Conclusions The efficacy and safety
The efficacy and safety of augmentation therapy withTCAs in of augmentation therapy withTCAs in SSRI-resistant patients should be SSRI-resistant patients should be monitored carefully, and patients monitored carefully, and patients prescribed antidepressants should be prescribed antidepressants should be screened for drug use/misuse. screened for drug use/misuse.
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Studies reporting on the toxicity of different Studies reporting on the toxicity of different antidepressants in overdose indicate that, antidepressants in overdose indicate that, compared with selective serotonin reuptake compared with selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, inhibitors (SSRIs), tricyclic antidepressants, particularly amitriptyline and dothiepin, particularly amitriptyline and dothiepin, are associated with an increased risk from are associated with an increased risk from overdose (Henry overdose (Henry et al et al, 1995; Shah , 1995; Shah et al et al, , 2001) . Although this information has aided 2001). Although this information has aided in the choice of antidepressants prescribed, in the choice of antidepressants prescribed, several questions remain about the profile several questions remain about the profile of toxicity of different antidepressants. of toxicity of different antidepressants. First, studies on antidepressant-related First, studies on antidepressant-related deaths have failed to distinguish between deaths have failed to distinguish between accidental deaths and deaths with suicidal accidental deaths and deaths with suicidal intent. Furthermore, no studies have exam-intent. Furthermore, no studies have examined ined whether certain antidepressant drugs whether certain antidepressant drugs are more likely to be used in multiple drug are more likely to be used in multiple drug overdoses, particularly in combination with overdoses, particularly in combination with other antidepressants or other psychoactive other antidepressants or other psychoactive drugs. With this in mind, the aims of this drugs. With this in mind, the aims of this paper were: to investigate the relative toxi-paper were: to investigate the relative toxicity of the major classes of antidepressant city of the major classes of antidepressant drugs, with the specific objective of asses-drugs, with the specific objective of assessing the cause of death as either accidental sing the cause of death as either accidental or intentional; and to analyse deaths where or intentional; and to analyse deaths where other drugs were present in combination other drugs were present in combination with antidepressants. with antidepressants.
METHOD METHOD
Sources of data Sources of data
The np-SAD database on drug-related deaths The np-SAD database on drug-related deaths Prescriptions written by hospital doctors Prescriptions written by hospital doctors are also included provided that they were are also included provided that they were dispensed in the community. Prescription dispensed in the community. Prescription cost analysis uses the concept of the cost analysis uses the concept of the 'defined daily dose', which is an international 'defined daily dose', which is an international system developed by the World Health system developed by the World Health Organization, and is defined as 'the Organization, and is defined as 'the assumed average maintenance dose per assumed average maintenance dose per day for a drug used on its main indication day for a drug used on its main indication in adults'. It also collects information on in adults'. It also collects information on 'average daily quantity' for antidepressants, 'average daily quantity' for antidepressants, a concept developed by an expert group a concept developed by an expert group convened by the Prescribing Support Unit convened by the Prescribing Support Unit and used to reflect more adequately and used to reflect more adequately general practitioner prescribing in England, general practitioner prescribing in England, based on several measures, including based on several measures, including defined daily doses and defined daily doses and British National British National Formulary Formulary information. Prescription cost information. Prescription cost analysis does not cover items dispensed in analysis does not cover items dispensed in hospitals or on private prescriptions. How-hospitals or on private prescriptions. However, because 90-98% of patients with ever, because 90-98% of patients with depression are seen by general practitioners depression are seen by general practitioners rather than psychiatrists (Thompson & rather than psychiatrists (Thompson & Thompson, 1989; McCarthy, 1993; Thompson, 1989; McCarthy, 1993; Donoghue & Tylee, 1996; Dunn Donoghue & Tylee, 1996; Dunn et al et al, , 1999; Middleton 1999; Middleton et al et al, 2001) , the exclusion , 2001), the exclusion of private prescriptions and hospital-of private prescriptions and hospitaldispensed prescriptions from our analysis dispensed prescriptions from our analysis should not appreciably affect the outcome should not appreciably affect the outcome of this study. of this study.
Study population Study population
The study population consisted of cases The study population consisted of cases reported by coroners in England and Wales reported by coroners in England and Wales to the np-SAD for deaths occurring during to the np-SAD for deaths occurring during the 3-year period 1998-2000. Cases for the 3-year period 1998-2000. Cases for the study were those who had a current the study were those who had a current prescription for antidepressant drugs at prescription for antidepressant drugs at the time of the fatality and where anti-the time of the fatality and where antidepressant drugs were implicated in the depressant drugs were implicated in the cause of death. Contribution to fatalities cause of death. Contribution to fatalities is defined by the np-SAD as being when is defined by the np-SAD as being when substances are specifically mentioned in substances are specifically mentioned in the cause of death by the coroner, or when the cause of death by the coroner, or when the drug type in the cause of death is not the drug type in the cause of death is not specified (e.g. 'polydrug toxicity') but the specified (e.g. 'polydrug toxicity') but the coroner reports that drugs were present coroner reports that drugs were present post-mortem. Cases are classified as intent-post-mortem. Cases are classified as intentional in the np-SAD database according to ional in the np-SAD database according to the coroner's verdict of 'suicide' or 'open' the coroner's verdict of 'suicide' or 'open' where suicide is likely. For the purposes of where suicide is likely. For the purposes of this study, 'accidental' includes deaths by this study, 'accidental' includes deaths by accidental overdose, traumatic accident or accidental overdose, traumatic accident or acute medical conditions. Cases are also acute medical conditions. Cases are also classified as those with or without a drug classified as those with or without a drug misuse history. misuse history.
Data analysis Data analysis
Antidepressants were assigned to four Antidepressants were assigned to four therapeutic classes according to the therapeutic classes according to the British British National Formulary National Formulary: tricyclic anti-: tricyclic antidepressants, monoamine oxidase inhibitors depressants, monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake in-(MAOIs), selective serotonin reuptake inhibitors (SSRIs) and other antidepressant hibitors (SSRIs) and other antidepressant drugs. The antidepressants included in each drugs. The antidepressants included in each therapeutic class can be seen in Table 2 . For therapeutic class can be seen in Table 2 . For each of the above classes of antidepressant, each of the above classes of antidepressant, the following variables were analysed: the following variables were analysed:
(a) (a) frequencies of drug mentions per frequencies of drug mentions per million prescriptions; the observed million prescriptions; the observed number of mentions was compared number of mentions was compared with the expected number of mentions, with the expected number of mentions, which was calculated by standardising which was calculated by standardising for the number of prescriptions; for the number of prescriptions;
(b) (b) frequencies of mentions in deaths by frequencies of mentions in deaths by single drug or in combination with single drug or in combination with other drugs; other drugs;
(c) (c) other drugs most likely to be implicated other drugs most likely to be implicated in deaths in combination with anti-in deaths in combination with antidepressants; depressants;
(d) (d) history of drug misuse or dependence; history of drug misuse or dependence;
(e) (e) the incidence of antidepressants by class the incidence of antidepressants by class in accidental and intentional deaths. in accidental and intentional deaths.
Statistical analysis Statistical analysis
We used prevalence ratios and their 95% We used prevalence ratios and their 95% confidence intervals (CIs) to compare confidence intervals (CIs) to compare differences in proportions. Standardised differences in proportions. Standardised mortality ratios and their 95% CIs were mortality ratios and their 95% CIs were used to compare observed and expected used to compare observed and expected number of deaths when standardised for number of deaths when standardised for the number of prescriptions for antidepres-the number of prescriptions for antidepressant drugs. The sant drugs. The w w 2 2 statistical test was used statistical test was used to test for differences between the anti-to test for differences between the antidepressant therapies. All analyses were depressant therapies. All analyses were undertaken using the Statistical Package undertaken using the Statistical Package for the Social Sciences for Windows version for the Social Sciences for Windows version 1.0 and CLINISTAT (Bland, 1990 ). 1.0 and CLINISTAT (Bland, 1990) .
RESULTS
Antidepressant classes implicated Antidepressant classes implicated in death compared with the in death compared with the number of prescriptions number of prescriptions During the study period there were 4167 During the study period there were 4167 drug-related deaths, of which 468 had an drug-related deaths, of which 468 had an antidepressant implicated in the deaths. antidepressant implicated in the deaths. Therefore, 11.2% of all drug-related deaths Therefore, 11.2% of all drug-related deaths involved antidepressant drugs. Among the involved antidepressant drugs. Among the 468 fatalities there were 473 mentions of 468 fatalities there were 473 mentions of antidepressants by class implicated in the antidepressants by class implicated in the deaths. A total of 285 cases had a single deaths. A total of 285 cases had a single antidepressant class implicated in the antidepressant class implicated in the deaths and there were 186 cases where deaths and there were 186 cases where two or more specific drug types were two or more specific drug types were implicated: an antidepressant class and implicated: an antidepressant class and another drug or multiple mentions of anti-another drug or multiple mentions of antidepressants with or without other drugs. depressants with or without other drugs. There were 498 mentions of specific anti-There were 498 mentions of specific antidepressants and there were 10 cases that depressants and there were 10 cases that had a mention of both nortriptyline and had a mention of both nortriptyline and amitriptyline. Because nortriptyline is a amitriptyline. Because nortriptyline is a metabolite of amitriptyline (Sanchez & metabolite of amitriptyline (Sanchez & Hyttel, 1999) these cases were included in Hyttel, 1999) these cases were included in fatalities associated with amitriptyline only. fatalities associated with amitriptyline only.
There was a substantial variation in the There was a substantial variation in the risk of death from the different antidepres-risk of death from the different antidepressant classes when compared with the sant classes when compared with the number of prescriptions. As can be seen number of prescriptions. As can be seen from Table 1 , the tricyclics (12 mentions from Table 1 , the tricyclics (12 mentions per million prescriptions) and the MAOIs per million prescriptions) and the MAOIs (14 mentions per million prescriptions) (14 mentions per million prescriptions) had a higher number of mentions per mil-had a higher number of mentions per million prescriptions compared with the SSRIs lion prescriptions compared with the SSRIs (2 mentions per million prescriptions). The (2 mentions per million prescriptions). The tricyclics prescribed most frequently were tricyclics prescribed most frequently were dothiepin, amitriptyline and lofepramine. dothiepin, amitriptyline and lofepramine. Both dothiepin and amitriptyline were Both dothiepin and amitriptyline were associated with significantly more deaths associated with significantly more deaths than would be expected when standardised than would be expected when standardised for the number of prescriptions but for the number of prescriptions but lofepramine was associated with signi-lofepramine was associated with significantly fewer mentions. In contrast to ficantly fewer mentions. In contrast to amitriptyline and dothiepin, the SSRIs were amitriptyline and dothiepin, the SSRIs were associated with significantly fewer men-associated with significantly fewer mentions than would be expected ( tions than would be expected (P P5 50.0001) 0.0001) when standardised for the number of pre-when standardised for the number of prescriptions, and this was the case for the four scriptions, and this was the case for the four most widely prescribed SSRIs: fluoxetine, most widely prescribed SSRIs: fluoxetine, paroxetine, citalopram and sertraline paroxetine, citalopram and sertraline (Table 2) . For the class of other anti- (Table 2) . For the class of other antidepressant drugs, 88% of fatalities were depressant drugs, 88% of fatalities were due to venlafaxine and the remainder were due to venlafaxine and the remainder were due to trazodone, which was associated due to trazodone, which was associated with significantly fewer mentions than with significantly fewer mentions than would be expected ( would be expected (P P5 50.05) when 0.05) when standardised for the number of pre-standardised for the number of prescriptions. Venlafaxine, however, had a scriptions. Venlafaxine, however, had a mortality rate not dissimilar to that seen mortality rate not dissimilar to that seen with the tricyclics, and there were 13 men-with the tricyclics, and there were 13 mentions per million prescriptions of this drug tions per million prescriptions of this drug (see Table 2 ). (see Table 2 ).
Antidepressants in combination Antidepressants in combination with other drugs implicated with other drugs implicated in mortality in mortality
Of 468 deaths in which antidepressant Of 468 deaths in which antidepressant drugs were implicated, 60% had anti-drugs were implicated, 60% had antidepressants solely implicated in death, depressants solely implicated in death, whereas antidepressants in combination whereas antidepressants in combination with other drugs were implicated in 40% with other drugs were implicated in 40% of cases. There was a significant relation-of cases. There was a significant relationship between whether antidepressants were ship between whether antidepressants were implicated alone or in combination with implicated alone or in combination with other drugs and the type of antidepres-other drugs and the type of antidepressant ( sant (w w 2 2 ¼55.39, 55.39, P P5 50.0001), and anti-0.0001), and antidepressant-related fatalities involving depressant-related fatalities involving multiple drug mentions were almost three multiple drug mentions were almost three times more likely to occur in SSRI-related times more likely to occur in SSRI-related cases than in tricyclic-related cases (per-cases than in tricyclic-related cases (percentage ratio centage ratio¼2.7, 95% CI 2.3-3.2; see 2.7, 95% CI 2.3-3.2; see Table 3 ). As can be seen from Table 4 , Table 3 ). As can be seen from Table 4 , the most frequently mentioned drugs in the most frequently mentioned drugs in combination with SSRIs were alcohol combination with SSRIs were alcohol (26%), tricyclic antidepressants (24%) (26%), tricyclic antidepressants (24%) 4 2 4 2 1.Excludes ten mentions probably recorded as a metabolite of amitriptyline. 1.Excludes ten mentions probably recorded as a metabolite of amitriptyline. * *P P5 50.05, **** 0.05, ****P P5 50.0001 for total expected deaths in comparison with total observed deaths. 0.0001 for total expected deaths in comparison with total observed deaths.
Drug misuse status of Drug misuse status of antidepressant-implicated deaths antidepressant-implicated deaths
Deaths related to antidepressant use in Deaths related to antidepressant use in combination with other drugs were more combination with other drugs were more likely to occur among drug misuse cases likely to occur among drug misuse cases than non-drug misuse cases ( than non-drug misuse cases (w w 2 2 ¼20.87, 20.87, P P5 50.0001). However, among these 'com-0.0001). However, among these 'combination' deaths there was no evidence that bination' deaths there was no evidence that being a drug misuser was related to a parti-being a drug misuser was related to a particular class of antidepressant ( cular class of antidepressant (w w 2 2 ¼1.55, 1.55, P P¼0.4). 0.4).
Accidental and intentional Accidental and intentional antidepressant deaths antidepressant deaths
As can be seen from Table 5 , 20% of As can be seen from Table 5 , 20% of mentions were associated with accidental mentions were associated with accidental deaths whereas 80% of mentions were deaths whereas 80% of mentions were associated with intentional deaths, suggest-associated with intentional deaths, suggesting that most deaths from antidepressant ing that most deaths from antidepressant drugs are due to suicide. Tricyclic anti-drugs are due to suicide. Tricyclic antidepressants are associated with a higher depressants are associated with a higher number of accidental and intentional number of accidental and intentional deaths, and significantly more accidental deaths, and significantly more accidental ( (P P5 50.0001) and intentional ( 0.0001) and intentional (P P5 50.001) 0.001) deaths were observed with the tricyclics deaths were observed with the tricyclics than would be expected when standardised than would be expected when standardised for the number of prescriptions. The SSRIs for the number of prescriptions. The SSRIs were associated were associated with significantly fewer with significantly fewer accidental ( accidental (P P5 50.0001) and intentional 0.0001) and intentional ( (P P5 50.0001) deaths than would be expected 0.0001) deaths than would be expected when standardised for the number of pre-when standardised for the number of prescriptions. For the other antidepressant scriptions. For the other antidepressant drugs there was no significant difference drugs there was no significant difference between the number of observed and between the number of observed and expected mentions when standardised for expected mentions when standardised for the number of prescriptions. Finally, there the number of prescriptions. Finally, there was no evidence of a relationship between was no evidence of a relationship between type of antidepressant and the occurrence type of antidepressant and the occurrence of an intentional or accidental death. of an intentional or accidental death.
DISCUSSION DISCUSSION
Fatalities related to tricyclic Fatalities related to tricyclic antidepressants antidepressants
The present study suggests that up to 80% The present study suggests that up to 80% of deaths from antidepressants are suicides, of deaths from antidepressants are suicides, and confirms previous findings that the and confirms previous findings that the tricyclics most likely to be implicated tricyclics most likely to be implicated in antidepressant-related deaths are ami-in antidepressant-related deaths are amitriptyline and dothiepin. Although the triptyline and dothiepin. Although the antidepressant properties of tricyclics are antidepressant properties of tricyclics are attributed to their ability to inhibit both attributed to their ability to inhibit both noradrenalin and serotonin reuptake, it noradrenalin and serotonin reuptake, it has been suggested that the increased has been suggested that the increased toxicity of these drugs in overdose may be toxicity of these drugs in overdose may be due to modulation of ion channel function due to modulation of ion channel function within the myocardium. Indeed the tri-within the myocardium. Indeed the tricyclics, particularly amitriptyline, have cyclics, particularly amitriptyline, have been associated with the inhibition of both been associated with the inhibition of both cardiac sodium (Na cardiac sodium (Na + + ) channels and potas-) channels and potassium (K sium (K + + ) channels, which is associated ) channels, which is associated with an increased risk of cardiac arrthymias with an increased risk of cardiac arrthymias and sudden death (Freeman and sudden death (Freeman et al et al, 1969; , 1969; Marshall & Forker, 1982; Ma & Henry, Marshall & Forker, 1982; Ma & Henry, 2001; Witchel 2001; Witchel et al et al, 2003) . Lofepramine , 2003) . Lofepramine was the only tricyclic associated with a was the only tricyclic associated with a lower incidence of mortality. Although the lower incidence of mortality. Although the mechanism of the lower toxicity of this mechanism of the lower toxicity of this drug has yet to be clarified, its membrane-drug has yet to be clarified, its membranestabilising activities (which may increase stabilising activities (which may increase the risk of cardiac arrthythmias) are much the risk of cardiac arrthythmias) are much lower than those of amitriptyline and lower than those of amitriptyline and desipramine (Darcy desipramine (Darcy et al et al, 2002) . , 2002).
Fatalities related to selective Fatalities related to selective serotonin reuptake inhibitors serotonin reuptake inhibitors
In contrast to amitriptyline and dothiepin, In contrast to amitriptyline and dothiepin, this study clearly suggests that the SSRIs this study clearly suggests that the SSRIs when taken on their own are safer in when taken on their own are safer in 4 4 4 4 overdose and are less likely to be implicated overdose and are less likely to be implicated in both intentional and accidental deaths. in both intentional and accidental deaths.
In addition to the treatment of depression, In addition to the treatment of depression, antidepressant drugs have been used for antidepressant drugs have been used for many other indications. In particular, SSRIs many other indications. In particular, SSRIs have been used in the treatment of general-have been used in the treatment of generalised anxiety disorders, obsessive-compulsive ised anxiety disorders, obsessive-compulsive disorders, social phobia, premenstrual disorders, social phobia, premenstrual dysphoric disorder and post-traumatic dysphoric disorder and post-traumatic stress disorder (Ables & Baughman, stress disorder (Ables & Baughman, 2003) . Because these disorders are likely 2003). Because these disorders are likely to carry a lower risk of suicide than depres-to carry a lower risk of suicide than depressive illnesses, this could also account for the sive illnesses, this could also account for the reduced toxicity of these drugs in overdose. reduced toxicity of these drugs in overdose. The present study suggests that when SSRIs The present study suggests that when SSRIs are implicated in death they are mostly are implicated in death they are mostly found in combination with other drugs, found in combination with other drugs, especially with tricyclics. In clinical prac-especially with tricyclics. In clinical practice, augmentation therapy involving the tice, augmentation therapy involving the prescription of an antidepressant alongside prescription of an antidepressant alongside another antidepressant drug of the same another antidepressant drug of the same or different pharmacological class has lar-or different pharmacological class has largely been used in patients with treatment-gely been used in patients with treatmentresistant depression or in patients who only resistant depression or in patients who only partially respond to antidepressants (Fava, partially respond to antidepressants (Fava, 2001) . Therefore, a possible explanation 2001). Therefore, a possible explanation for the increased number of combination for the increased number of combination deaths with SSRIs is that these individuals deaths with SSRIs is that these individuals were suffering from a treatment-resistant were suffering from a treatment-resistant depression and tricyclics may have been depression and tricyclics may have been prescribed concurrently, accounting for prescribed concurrently, accounting for the fatal outcome. The SSRIs have been the fatal outcome. The SSRIs have been shown also to differ in the extent of their shown also to differ in the extent of their inhibition of the cytochrome P-450 inhibition of the cytochrome P-450 enzymes of the liver, which are crucial enzymes of the liver, which are crucial in the metabolism of numerous drugs in the metabolism of numerous drugs (Richelson, 1997) , raising the possibility (Richelson, 1997), raising the possibility of drug-drug interactions in patients taking of drug-drug interactions in patients taking multiple medications. Enzyme CYP2D6 is multiple medications. Enzyme CYP2D6 is considered the principal P-450 cytochrome considered the principal P-450 cytochrome enzyme in the clearance of tricyclics, enzyme in the clearance of tricyclics, and data from and data from in vitro in vitro studies suggest studies suggest that the rank order of potency for that the rank order of potency for inhibition of CYP2D6 by antidepressants inhibition of CYP2D6 by antidepressants is paroxetine is paroxetine 5 5 fluoxetine fluoxetine 4 4 sertraline sertraline 4 4 fluvoxamine fluvoxamine 4 4 venlafaxine venlafaxine 4 4 mirtazapine mirtazapine (Vaughan, 1988; Crewe (Vaughan, 1988; Crewe et al et al, 1992) . There-, 1992) . Therefore, it is possible that by inhibiting fore, it is possible that by inhibiting CYP2D6 the SSRIs may increase plasma CYP2D6 the SSRIs may increase plasma levels of tricyclics, thereby increasing the levels of tricyclics, thereby increasing the toxic effects associated with these drugs. toxic effects associated with these drugs. This could be an explanation for the pre-This could be an explanation for the present findings of increased risk of death from sent findings of increased risk of death from SSRIs in combination with tricyclics, SSRIs in combination with tricyclics, although the data at present do not seem although the data at present do not seem to support this hypothesis because higher to support this hypothesis because higher rates of deaths involving SSRIs such as rates of deaths involving SSRIs such as fluoxetine and paroxetine were not found. fluoxetine and paroxetine were not found. Although we do not know what percentage Although we do not know what percentage of the combination deaths from SSRIs and of the combination deaths from SSRIs and tricyclics occurred as a result of prescrip-tricyclics occurred as a result of prescription within the normal clinical guidelines, tion within the normal clinical guidelines, the present findings do suggest that the the present findings do suggest that the clinical efficacy of augmentation therapy clinical efficacy of augmentation therapy in SSRI-resistant patients should be in SSRI-resistant patients should be monitored carefully because of the risk of monitored carefully because of the risk of suicide. suicide.
Antidepressant-related deaths Antidepressant-related deaths and drug misuse and drug misuse
The present study is the first to demonstrate The present study is the first to demonstrate that cases involving antidepressants with that cases involving antidepressants with other drugs are significantly more likely to other drugs are significantly more likely to involve drug addicts. The other drugs that involve drug addicts. The other drugs that are most likely to be implicated in are most likely to be implicated in combination with the antidepressants were combination with the antidepressants were alcohol and opiate-based drugs. These find-alcohol and opiate-based drugs. These findings suggest that general practitioners and ings suggest that general practitioners and psychiatrists should screen for drug use/ psychiatrists should screen for drug use/ misuse patterns in patients being prescribed misuse patterns in patients being prescribed antidepressants and should prescribe cau-antidepressants and should prescribe cautiously for these individuals. tiously for these individuals.
Venlafaxine-related fatalities Venlafaxine-related fatalities
This study suggests that, of the miscella-This study suggests that, of the miscellaneous group of antidepressants, venlafaxine neous group of antidepressants, venlafaxine may be more toxic in overdose than other may be more toxic in overdose than other drugs in this class. This finding supports drugs in this class. This finding supports evidence from a recent study published by evidence from a recent study published by Buckley & McManus (2002) . Venlafaxine Buckley & McManus (2002) . Venlafaxine is a serotonin and noradrenalin reuptake is a serotonin and noradrenalin reuptake inhibitor and at low doses is very similar inhibitor and at low doses is very similar to SSRIs in that it predominantly inhibits to SSRIs in that it predominantly inhibits the reuptake of serotonin, although at the reuptake of serotonin, although at higher doses noradrenalin reuptake inhibi-higher doses noradrenalin reuptake inhibition is predominant. Furthermore, recent tion is predominant. Furthermore, recent case studies have suggested a link between case studies have suggested a link between cardiac illness/failure and venlafaxine, and cardiac illness/failure and venlafaxine, and there is evidence that this drug blocks Na there is evidence that this drug blocks Na + + channels (Blythe & Hackett, 1999 ; Khalifa channels (Blythe & Hackett, 1999; Khalifa et al et al, 1999; Reznik , 1999; Reznik et al et al, 1999; Drent , 1999; Drent et al et al, , 2003) . However, the other drugs most 2003). However, the other drugs most likely to be found in combination with likely to be found in combination with venlafaxine were antipsychotics, which venlafaxine were antipsychotics, which were implicated in 38.9% of cases in this were implicated in 38.9% of cases in this group. The higher rate of antipsychotic group. The higher rate of antipsychotic prescribing with venlafaxine suggests that prescribing with venlafaxine suggests that a different patient group may have been a different patient group may have been involved, possibly the seriously depressed involved, possibly the seriously depressed or dual-diagnosis patients who are difficult or dual-diagnosis patients who are difficult to treat and possibly at a greater risk from to treat and possibly at a greater risk from suicide. suicide. 4 5 4 5 TCAs, tricyclic antidepressants; MAOIs, monoamine oxidase inhibitors; SSRIs, selective serotonin reuptake inhibitors. TCAs, tricyclic antidepressants; MAOIs, monoamine oxidase inhibitors; SSRIs, selective serotonin reuptake inhibitors. *** ***P P5 50.001, **** 0.001, ****P P5 50.00001 for total expected deaths in comparison with total observed deaths. 0.00001 for total expected deaths in comparison with total observed deaths.
Limitations and summary Limitations and summary
It is important to note that there are several It is important to note that there are several reasons apart from the toxicity of reasons apart from the toxicity of antidepressant medication that can lead to antidepressant medication that can lead to a fatal overdose. These include treatment-a fatal overdose. These include treatmentresistant depression, non-response to the resistant depression, non-response to the antidepressant therapy, medication non-antidepressant therapy, medication noncompliance, duration of illness, history of compliance, duration of illness, history of antidepressant treatments and undertreat-antidepressant treatments and undertreatment of depression. Previously it has been ment of depression. Previously it has been suggested that in primary care practice suggested that in primary care practice tricyclic antidepressants are frequently pre-tricyclic antidepressants are frequently prescribed at doses below those that are shown scribed at doses below those that are shown to be efficacious in randomised controlled to be efficacious in randomised controlled clinical trials (Donoghue & Taylor, 2000) , clinical trials (Donoghue & Taylor, 2000) , with studies showing that up to 88% of with studies showing that up to 88% of patients receiving tricyclics were on doses patients receiving tricyclics were on doses below those recommended in the national below those recommended in the national guidelines (Donoghue & Tylee, 1996) . guidelines (Donoghue & Tylee, 1996) . However, a recent meta-analysis of However, a recent meta-analysis of randomised controlled clinical trials randomised controlled clinical trials comparing the effects of low-dose and comparing the effects of low-dose and standard-dose tricyclics suggests that low standard-dose tricyclics suggests that low dosage regimes are more effective than dosage regimes are more effective than placebo in the treatment of depression, placebo in the treatment of depression, and may or may not be as effective as and may or may not be as effective as standard dosage regimes but that the standard dosage regimes but that the drop-out rate is lower because they produce drop-out rate is lower because they produce fewer side-effects (Furukawa fewer side-effects (Furukawa et al et al, 2002 (Furukawa et al et al, ). , 2002 . This is in contrast to the SSRIs, which are This is in contrast to the SSRIs, which are associated with the lowest level of mortality associated with the lowest level of mortality and are almost always prescribed at and are almost always prescribed at efficacious doses in primary care settings efficacious doses in primary care settings (Donoghue & Tylee, 1996; Dunn (Donoghue & Tylee, 1996; Dunn et al et al, , 1999 ). Furthermore, not all coroners report 1999). Furthermore, not all coroners report to the np-SAD database, although the to the np-SAD database, although the response rate from the coroners in England response rate from the coroners in England and Wales has been estimated to be as high and Wales has been estimated to be as high as about 95% (Oyefeso as about 95% (Oyefeso et al et al, 1999) . , 1999). Despite these limitations, the present study Despite these limitations, the present study clearly suggests that, although tricyclic clearly suggests that, although tricyclic antidepressants are more toxic in overdose, antidepressants are more toxic in overdose, the SSRIs are largely implicated in death in the SSRIs are largely implicated in death in combination with other drugs, especially combination with other drugs, especially tricyclics, suggesting either a treatment-tricyclics, suggesting either a treatmentresistant depression or non-response to resistant depression or non-response to pharmacotherapy. Therefore, suicide risk pharmacotherapy. Therefore, suicide risk should be monitored carefully when aug-should be monitored carefully when augmentation therapy is used in SSRI-resistant mentation therapy is used in SSRI-resistant patients. Furthermore, all patients pre-patients. Furthermore, all patients prescribed antidepressants should be screened scribed antidepressants should be screened routinely for a history of drug use/misuse. routinely for a history of drug use/misuse. & & Although selective serotonin reuptake inhibitors (SSRIs) are safer in overdose than Although selective serotonin reuptake inhibitors (SSRIs) are safer in overdose than the tricyclic antidepressants, deaths in which SSRIs are implicated are most likely to the tricyclic antidepressants, deaths in which SSRIs are implicated are most likely to be in combination with other drugs, particularly tricyclics.Therefore, the efficacy and be in combination with other drugs, particularly tricyclics.Therefore, the efficacy and safety of augmentation therapy in SSRI-resistant patients should be monitored safety of augmentation therapy in SSRI-resistant patients should be monitored carefully. carefully.
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